anti-Pembrolizumab ELISA Kit (Keytruda®) (ab237666)

Overview

  • Product name

    anti-Pembrolizumab ELISA Kit (Keytruda®)
    See all Pembrolizumab kits
  • Detection method

    Colorimetric
  • Sample type

    Serum, Plasma
  • Assay type

    Sandwich (qualitative)
  • Assay duration

    Multiple steps standard assay
  • Species reactivity

    Reacts with: Human
  • Product overview

    anti-Pembrolizumab ELISA Kit (Keytruda®) (ab237666) is a highly specific and sensitive kit designed for the in vitro qualitative determination of antibody against Pembrolizumab in biological matrices such as human serum and plasma.


    Pembrolizumab (Keytruda®) is an antibody drug that targets the cell surface receptor programmed cell death protein 1 (PD-1) found on T cells. By preventing the binding of its ligands (PD-L1 and PD-L2), pembrolizumab induces an antitumor immune response. Upregulation of PD-1 ligands is a mechanism for tumors to evade antitumor immune response; when PD-1 binds its ligand, the T cell receives an inhibitory signal leading to T cell anergy and blockade of anti-tumour immune response. Instead of directly targeting tumor tissue to induce tumor cell death, pembrolizumab acts as a checkpoint inhibitor to stimulate immune responses to eliminate cancer cells. However, some patients develop unwanted immunogenicity, which leads to production of anti-drug-antibodies (ADAs) inactivating the therapeutic effects of the treatment and, in rare cases, inducing adverse effects.

  • Tested applications

    Suitable for: Sandwich ELISAmore details
  • Platform

    Microplate

Properties

  • Storage instructions

    Store at +4°C. Please refer to protocols.
  • Components 96 tests
    Assay Buffer 1 x 50ml
    Micro ELISA Plate 1 unit
    Negative Control 1 x 0.5ml
    Peroxidase Conjugate 1 x 12ml
    Plate sealers 2 units
    Positive Control 1 x 0.25ml
    Stop Solution 1 x 12ml
    TMB substrate 1 x 12ml
    Wash buffer (20X) 1 x 50ml
  • Relevance

    Pembrolizumab (Keytruda®) is an antibody drug that targets the cell surface receptor programmed cell death protein 1 (PD-1) found on T cells. By preventing the binding of its ligands (PD-L1 and PD-L2), pembrolizumab induces an antitumor immune response. Upregulation of PD-1 ligands is a mechanism for tumors to evade antitumor immune response; when PD-1 binds its ligand, the T cell receives an inhibitory signal leading to T cell anergy and blockade of anti-tumour immune response. Instead of directly targeting tumor tissue to induce tumor cell death, pembrolizumab acts as a checkpoint inhibitor to stimulate immune responses to eliminate cancer cells.
  • Alternative names

    • Keytruda

Applications

Our Abpromise guarantee covers the use of ab237666 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
Sandwich ELISA Use at an assay dependent concentration.

Protocols

References

ab237666 has not yet been referenced specifically in any publications.

Customer reviews and Q&As

There are currently no Customer reviews or Questions for ab237666.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES"
For licensing inquiries, please contact partnerships@abcam.com

Sign up